Unnamed: 0,title,date,stock,sentiment
595116.0,"Haemonetics Announces Blood Filter Supply Agreement And Sale Of Puerto Rico-Based Manufacturing Operations To GVS, S.p.A",2020-06-03 06:46:00-04:00,HAE,positive
595117.0,Haemonetics Announces Sale Of U.S. Blood Donor Management Software Solution Assets To The GPI Group; Terms Not Disclosed,2020-05-28 16:19:00-04:00,HAE,positive
595118.0,"Raymond James Maintains Outperform on Haemonetics, Lowers Price Target to $125",2020-05-06 07:29:00-04:00,HAE,negative
595119.0,"Needham Maintains Buy on Haemonetics, Lowers Price Target to $132",2020-05-05 13:16:00-04:00,HAE,negative
595120.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,HAE,positive
595121.0,"Haemonetics Q4 EPS $0.690 Misses $0.730 Estimate, Sales $238.492M Miss $247.150M Estimate",2020-05-05 06:12:00-04:00,HAE,negative
595122.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,HAE,neutral
595123.0,"Raymond James Maintains Outperform on Haemonetics, Lowers Price Target to $130",2020-04-07 07:39:00-04:00,HAE,negative
595124.0,"Haemonetics Reports Purchase Of enicor, No Terms Disclosed",2020-04-02 06:47:00-04:00,HAE,negative
595125.0,"Haemonetics Appoints Anila Lingamneni Executive Vice President, Chief Technology Officer",2020-03-30 16:24:00-04:00,HAE,neutral
595126.0,"Morgan Stanley Maintains Overweight on Haemonetics, Lowers Price Target to $138",2020-03-27 09:34:00-04:00,HAE,negative
595127.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,HAE,neutral
595128.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,HAE,positive
595129.0,"Raymond James Maintains Outperform on Haemonetics, Raises Price Target to $150",2020-02-05 07:20:00-05:00,HAE,neutral
595130.0,68 Biggest Movers From Yesterday,2020-02-05 05:56:00-05:00,HAE,neutral
595131.0,55 Stocks Moving In Tuesday's Mid-Day Session,2020-02-04 12:35:00-05:00,HAE,neutral
595132.0,"The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares",2020-02-04 07:51:00-05:00,HAE,negative
595133.0,Haemonetics Raises FY20 Adj. EPS Guidance From $3.10-$3.20 To $3.30-$3.40 vs $3.18 Est.,2020-02-04 06:16:00-05:00,HAE,neutral
595134.0,"Haemonetics Q3 EPS $0.94 Beats $0.76 Estimate, Sales $258.97M Beat $255.4M Estimate",2020-02-04 06:15:00-05:00,HAE,neutral
595135.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,HAE,neutral
595136.0,"Raymond James Maintains Outperform on Haemonetics, Lowers Price Target to $145",2020-01-23 07:50:00-05:00,HAE,negative
595137.0,Haemonetics Acquires Intellectual Property Assets Relating To TEG 6s Hemostasis Analyzer System From CoraMed; Terms Not Disclosed,2020-01-14 06:34:00-05:00,HAE,positive
595138.0,"Benzinga's Top Upgrades, Downgrades For January 10, 2020",2020-01-10 12:16:00-05:00,HAE,positive
595139.0,"Needham Initiates Coverage On Haemonetics with Buy Rating, Announces $138 Price Target",2020-01-10 07:38:00-05:00,HAE,neutral
595140.0,"Haemonetics Q2 EPS $0.87 Beats $0.69 Estimate, Sales $252.6M Beat $249.77M Estimate; Sees FY20 Adj. EPS $3.10-$3.20 vs $3.06 Est.",2019-11-01 06:17:00-04:00,HAE,neutral
595141.0,Stocks That Hit 52-Week Highs On Monday,2019-08-19 10:53:00-04:00,HAE,neutral
595142.0,Stocks That Hit 52-Week Highs On Friday,2019-08-16 10:35:00-04:00,HAE,neutral
595143.0,"The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering",2019-08-14 07:50:00-04:00,HAE,negative
595144.0,Stocks That Hit 52-Week Highs On Tuesday,2019-08-13 10:28:00-04:00,HAE,neutral
595145.0,"The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2",2019-08-09 07:19:00-04:00,HAE,negative
595146.0,Stocks That Set New 52-Week Highs Thursday,2019-08-08 12:19:00-04:00,HAE,neutral
595147.0,10 Biggest Price Target Changes For Wednesday,2019-08-07 08:51:00-04:00,HAE,neutral
595148.0,"Morgan Stanley Maintains Overweight on Haemonetics, Raises Price Target to $148",2019-08-07 08:28:00-04:00,HAE,negative
595149.0,"Raymond James Maintains Outperform on Haemonetics, Raises Price Target to $150",2019-08-07 07:44:00-04:00,HAE,neutral
595150.0,85 Biggest Movers From Yesterday,2019-08-07 05:39:00-04:00,HAE,neutral
595151.0,68 Stocks Moving In Tuesday's Mid-Day Session,2019-08-06 13:55:00-04:00,HAE,neutral
595152.0,Haemonetics shares are trading higher after the company reported better-than-expected Q1 EPS and sales results. The company also raised FY20 EPS guidance above analyst estimates.,2019-08-06 10:41:00-04:00,HAE,positive
595153.0,New 52-Week-High Achievers For Tuesday Morning,2019-08-06 10:23:00-04:00,HAE,neutral
595154.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,HAE,positive
595155.0,Haemonetics Raises FY20 Adn. EPS Guidance From $2.80-$3.00 To $2.95-$3.15 vs $2.94 Est.,2019-08-06 06:22:00-04:00,HAE,neutral
595156.0,"Haemonetics Q1 Adj. EPS $0.81 Beats $0.63 Estimate, Sales $238M Beat $237.95M Estimate",2019-08-06 06:21:00-04:00,HAE,neutral
595157.0,"The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug",2019-07-25 07:21:00-04:00,HAE,negative
595158.0,Stocks that Broke 52-Week Highs Tuesday,2019-07-23 14:39:00-04:00,HAE,negative
595159.0,Haemonetics shares are trading higher after the company received FDA clearance for expanded use of the TEG 6s Hemostasis Analyzer System for use in adult trauma settings.,2019-05-14 15:29:00-04:00,HAE,negative
595160.0,"Benzinga's Top Upgrades, Downgrades For May 14, 2019",2019-05-14 09:20:00-04:00,HAE,positive
595161.0,"Raymond James Upgrades Haemonetics Corporation Common Stock to Outperform, Announces $110 Price Target",2019-05-14 06:31:00-04:00,HAE,neutral
595162.0,"The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex",2019-05-07 08:20:00-04:00,HAE,neutral
595163.0,Haemonetics Sees FY20 Adj. EPS $2.80-$3.00 vs $2.89 Est.,2019-05-07 06:25:00-04:00,HAE,neutral
595164.0,Haemonetics  Reports $500M Buyback,2019-05-07 06:23:00-04:00,HAE,neutral
595165.0,"Haemonetics Q4 Adj. EPS $0.61 Beats $0.55 Estimate, Sales $249.3M Miss $250.63M Estimate",2019-05-07 06:23:00-04:00,HAE,negative
595166.0,50 Biggest Movers From Yesterday,2019-02-06 05:03:00-05:00,HAE,neutral
595167.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-02-05 12:35:00-05:00,HAE,neutral
595168.0,"Haemonetics shares are trading lower after the company reported Q3 sales of $247.356 million, missing the $250.13 million estimate.",2019-02-05 10:40:00-05:00,HAE,negative
595169.0,"Haemonetics Reaffirms FY19 Adj. EPS Guidance Of $2.25-$2.35 vs $2.33 Est., Raises Cash Flow Guidance From  $150M-$175M To $160M-$185M",2019-02-05 06:16:00-05:00,HAE,neutral
595170.0,"Haemonetics Q3 Adj. EPS $0.63 Beats $0.59 Estimate, Sales $247.356M Miss $250.13M Estimate",2019-02-05 06:13:00-05:00,HAE,negative
595171.0,Haemonetics Corporation Raises FY19 Adj. EPS Guidance From $2.00-$2.30 To $2.25-$2.35 vs $2.29 Est.,2018-11-06 07:31:00-05:00,HAE,neutral
595172.0,"Haemonetics Corporation Q2 Adj. EPS $0.56 Beats $0.54 Estimate, Sales $241.581M Beat $233.45M Estimate",2018-11-06 07:29:00-05:00,HAE,neutral
595173.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,HAE,positive
595174.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,HAE,neutral
595175.0,"Stocks Which Set New 52-Week High Yesterday, October 1st",2018-10-02 09:20:00-04:00,HAE,neutral
595176.0,"The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares",2018-10-02 09:10:00-04:00,HAE,positive
595177.0,"Stocks Which Set New 52-Week High Friday, September 14th",2018-09-17 09:28:00-04:00,HAE,neutral
595178.0,"Stocks Which Set New 52-Week High Friday, September 7th",2018-09-10 16:36:00-04:00,HAE,neutral
595179.0,"Stocks Which Set New 52-Week High Yesterday, September 4th",2018-09-05 10:22:00-04:00,HAE,neutral
595180.0,"The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results",2018-09-05 08:28:00-04:00,HAE,positive
595181.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,HAE,neutral
595182.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,HAE,neutral
595183.0,"The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage",2018-08-31 08:29:00-04:00,HAE,positive
595184.0,"Stocks Which Set New 52-Week High Yesterday, August 29th",2018-08-30 11:47:00-04:00,HAE,neutral
595185.0,"The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration",2018-08-30 08:02:00-04:00,HAE,neutral
595186.0,"Stocks Which Set New 52-Week High Yesterday, August 28th",2018-08-29 11:13:00-04:00,HAE,neutral
595187.0,"The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent",2018-08-29 07:54:00-04:00,HAE,positive
595188.0,"Stocks Which Set New 52-Week High Yesterday, August 7th",2018-08-08 11:01:00-04:00,HAE,neutral
595189.0,"Morgan Stanley Maintains Overweight on Haemonetics, Raises Price Target to $120",2018-08-08 09:55:00-04:00,HAE,negative
595190.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,HAE,positive
595191.0,"Stocks Which Set New 52-Week High Yesterday, July 26th:",2018-07-27 10:42:00-04:00,HAE,neutral
595192.0,"Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter",2018-07-27 08:44:00-04:00,HAE,neutral
595193.0,"Stocks Which Set New 52-Week High Yesterday, July 24th:",2018-07-25 12:14:00-04:00,HAE,neutral
595194.0,"Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering",2018-07-24 08:53:00-04:00,HAE,positive
595195.0,Stocks Which Set New 52-Week High Yesterday,2018-07-20 09:05:00-04:00,HAE,neutral
595196.0,"Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares",2018-07-18 08:42:00-04:00,HAE,positive
595197.0,"Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug",2018-06-15 09:13:00-04:00,HAE,neutral
595198.0,"Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study",2018-06-07 07:58:00-04:00,HAE,neutral
595199.0,"Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate",2018-06-06 08:38:00-04:00,HAE,positive
595200.0,"Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index",2018-06-05 08:05:00-04:00,HAE,positive
595201.0,"Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time",2018-05-31 08:22:00-04:00,HAE,positive
595202.0,"Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict",2018-05-22 08:05:00-04:00,HAE,positive
595203.0,"Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved",2018-05-18 08:00:00-04:00,HAE,positive
595204.0,"Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More",2018-05-17 08:27:00-04:00,HAE,neutral
595205.0,"Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway",2018-05-15 08:44:00-04:00,HAE,positive
595206.0,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",2018-05-10 09:44:00-04:00,HAE,neutral
595207.0,5 Biggest Price Target Changes For Wednesday,2018-05-09 10:05:00-04:00,HAE,neutral
595208.0,"Morgan Stanley Maintains Overweight on Haemonetics, Raises Price Target to $100",2018-05-09 07:33:00-04:00,HAE,negative
595209.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,HAE,neutral
595210.0,Haemonetics Corporation Sees FY19 Adj. EPS $2.00-$2.30 vs 2.09 Est.,2018-05-08 06:14:00-04:00,HAE,neutral
595211.0,"Haemonetics Q4 EPS $0.43 Beats $0.42 Estimate, Sales $233.552M Beat $227.12M Estimate",2018-05-08 06:12:00-04:00,HAE,neutral
595212.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,HAE,neutral
595213.0,Haemonetics' Plasma Tool Enhancement Gets 510(K) Clearance,2018-04-02 13:42:00-04:00,HAE,neutral
595214.0,Haemonetics Board Authorizes $260M Share Buyback,2018-02-06 06:18:00-05:00,HAE,positive
595215.0,"Morgan Stanley Turns Bullish On Haemonetics, Raymond James Moves To The Sidelines",2018-01-02 13:19:00-05:00,HAE,neutral
595216.0,Raymond James Upgrades Haemonetics to Market Perform,2018-01-02 10:14:00-05:00,HAE,neutral
595217.0,Morgan Stanley Upgrades Haemonetics to Overweight,2018-01-02 07:20:00-05:00,HAE,negative
595218.0,56 Biggest Movers From Yesterday,2017-11-08 04:40:00-05:00,HAE,neutral
595219.0,"Haemonetics Shares Up 8.88%; Earlier, Co. Reported Q2 Adj. EPS $0.48 vs $0.41 Est., Sales $225M vs $219.26M Est.; Co. Raised FY18 Outlook, Adj. EPS From $1.55-$1.65 to $1.65-$1.75 vs $1.61 Est., Sales Appox. Flat With FY17",2017-11-07 14:21:00-05:00,HAE,positive
595220.0,45 Stocks Moving In Tuesday's Mid-Day Session,2017-11-07 12:41:00-05:00,HAE,neutral
595221.0,"Haemonetics Q2 Adj. EPS $0.33 vs $0.31 Est., Sales $211.0M vs $212.1M Est.",2017-08-07 06:11:00-04:00,HAE,neutral
595222.0,"Earnings Scheduled For August 7, 2017",2017-08-07 05:03:00-04:00,HAE,neutral
595223.0,Believe In The Haemonetics Turnaround Story; JMP Upgrades To Market Outperform,2017-07-13 12:58:00-04:00,HAE,neutral
595224.0,15 Biggest Mid-Day Gainers For Thursday,2017-07-13 12:27:00-04:00,HAE,neutral
595225.0,"Benzinga's Top Upgrades, Downgrades For July 13, 2017",2017-07-13 09:22:00-04:00,HAE,positive
595226.0,JMP Securities Upgrades Haemonetics to Market Outperform,2017-07-13 07:21:00-04:00,HAE,positive
595227.0,"Companies Holding Analyst/Investor Days Today Include Enphase Energy, Haemonetics Corp., United Technologies, and Nabriva Therapeutics",2017-06-19 08:54:00-04:00,HAE,positive
595230.0,Haemonetics Sees FY 2018 EPS $1.55 to $1.65 vs $1.59 Est,2017-05-08 06:11:00-04:00,HAE,neutral
595231.0,"Haemonetics Q1 EPS $0.39 vs $0.38 Est, Sales $228.07M vs $219.42M Est",2017-05-08 06:10:00-04:00,HAE,neutral
595232.0,Barrington Research Downgrades Haemonetics To Market Perform,2017-02-07 09:24:00-05:00,HAE,neutral
595233.0,Haemonetics Sees FY 2017 At High End of Range,2017-02-06 06:12:00-05:00,HAE,neutral
595234.0,"Haemonetics Q3 EPS $0.43 vs $0.40 Est, Revenue $227.84M vs $220.31M Est",2017-02-06 06:12:00-05:00,HAE,neutral
595235.0,"Earnings Scheduled For February 6, 2017",2017-02-06 04:36:00-05:00,HAE,neutral
595236.0,Barrington Research Upgrades Haemonetics Corporation Common Stock to Outperform,2016-11-08 09:33:00-05:00,HAE,neutral
595237.0,Haemonetics Reaffirms FY 2017 Guidance,2016-11-07 06:16:00-05:00,HAE,neutral
595238.0,"Haemonetics Q2 EPS $0.38 vs $0.35 Est, Revenue $220.25M vs $210.72M Est",2016-11-07 06:15:00-05:00,HAE,neutral
595239.0,Mid-Morning Market Update:  Markets Open Higher; Citigroup Profit Tops Expectations,2016-10-14 10:28:00-04:00,HAE,positive
595240.0,Sidoti & Co. Downgrades Haemonetics to Neutral,2016-08-15 09:17:00-04:00,HAE,neutral
595241.0,Barrington Research Downgrades Haemonetics to Market Perform,2016-08-03 08:22:00-04:00,HAE,neutral
595242.0,7 Biggest Price Target Changes For Tuesday,2016-08-02 09:54:00-04:00,HAE,neutral
595243.0,BMO Capital Highlights This Week's MedTech Earnings,2016-08-01 15:14:00-04:00,HAE,neutral
595244.0,Mid-Day Market Update: Crude Oil Down 3%; FleetMatics Group Shares Rise Following Acquisition News,2016-08-01 12:18:00-04:00,HAE,negative
595245.0,Haemonetics Names Bil Burke as CFO,2016-08-01 06:11:00-04:00,HAE,neutral
595246.0,"Earnings Scheduled For August 1, 2016",2016-08-01 04:02:00-04:00,HAE,neutral
595247.0,"Goldman Takes Haemonetics Off Sell List, Upgrades To Neutral",2016-05-16 11:27:00-04:00,HAE,neutral
595248.0,Benzinga's Top Upgrades,2016-05-16 09:05:00-04:00,HAE,positive
595249.0,"Goldman Sachs Upgrades Haemonetics to Neutral, Raises PT to $29.00, Removed From Americas Sell List",2016-05-16 06:16:00-04:00,HAE,neutral
595250.0,"Haemonetics Sees FY17 Sales $850M-$875M vs 917M Est., Adj. EPS $1.40-$1.50 vs $1.56 Est.",2016-05-09 17:06:00-04:00,HAE,neutral
595251.0,Mid-Afternoon Market Update: Dow Rises Over 100 Points; Crude Oil Down 2.5%,2016-05-02 14:35:00-04:00,HAE,negative
595252.0,Mid-Day Market Update: Opower Gains On Acquisition News; BIND Therapeutics Shares Dip,2016-05-02 12:21:00-04:00,HAE,positive
595253.0,"Haemonetics Q4 EPS $0.37 vs $0.46 est, Revenue $243.2M vs $245.0M est",2016-05-02 06:19:00-04:00,HAE,neutral
595254.0,"Earnings Scheduled For May 2, 2016",2016-05-02 04:18:00-04:00,HAE,neutral
595255.0,"After-Hours Recap: Big Banks, Liquidity Services's DoD Deal, Haemonetics' CFO & More",2016-04-14 17:17:00-04:00,HAE,neutral
595256.0,Haemonetics CFO Christopher Lindop To Retire Effective May 27th 2016,2016-04-14 16:02:00-04:00,HAE,positive
595257.0,Earnings Recap For February 1,2016-02-01 16:35:00-05:00,HAE,neutral
595258.0,"Haemonetics Reaffirms FY 2016 Guidance; EPS $1.65 to $1.75 vs $1.71 est, Revenue $910M to $920M vs $912M est",2016-02-01 06:04:00-05:00,HAE,neutral
595259.0,"Haemonetics Q3 EPS $0.48 vs $0.46 est, Revenue $233.4M vs $237.4M est",2016-02-01 06:01:00-05:00,HAE,neutral
595260.0,"Earnings Scheduled For February 1, 2016",2016-02-01 04:01:00-05:00,HAE,neutral
595261.0,BTIG Research Earlier Initiated Coverage on Haemonetics at Neutral,2015-12-14 10:39:00-05:00,HAE,neutral
595262.0,Morning Market Losers,2015-11-23 09:57:00-05:00,HAE,negative
595263.0,Benzinga's Top Downgrades,2015-11-23 09:17:00-05:00,HAE,positive
595264.0,Benzinga's Top #PreMarket Losers,2015-11-23 08:18:00-05:00,HAE,negative
595265.0,Raymond James Downgrades Haemonetics to Underperform,2015-11-23 07:54:00-05:00,HAE,neutral
595266.0,"Haemonetics Sees Q2 EPS $0.44 vs $0.53 est, Revenue $220M vs $243M est",2015-11-04 06:10:00-05:00,HAE,neutral
595267.0,Haemonetics Sees FY Revenue $910M to $920 vs $926M est,2015-11-04 06:08:00-05:00,HAE,neutral
595268.0,"Haemonetics Q2 EPS $0.44 vs $0.39 est, Revenue $220M vs $221.5M est",2015-11-04 06:08:00-05:00,HAE,neutral
595269.0,Morning Market Losers,2015-10-06 09:50:00-04:00,HAE,negative
595270.0,5 Stocks You Should Be Watching Today,2015-10-06 04:48:00-04:00,HAE,neutral
595271.0,UPDATE: Haemonetics Cuts FY16 Adj. EPS Outlook from $1.98-$2.08 to $1.65-$1.75 vs $2.02 Est.,2015-10-05 16:32:00-04:00,HAE,negative
595272.0,UPDATE: Haemonetics Sees FY16 Sales in $910M-$920M Range vs $946.8M Est.,2015-10-05 16:31:00-04:00,HAE,neutral
595273.0,UPDATE: Haemonetics Cuts FY16 Sales Growth Guidance from 4-6% to 0-1%,2015-10-05 16:31:00-04:00,HAE,positive
595274.0,Haemonetics Sees Q2 Adj. EPS $0.40 vs $0.39 Est.,2015-10-05 16:30:00-04:00,HAE,neutral
595275.0,Haemonetics Sees Q2 Sales ~$220M vs $226.5M Est.,2015-10-05 16:30:00-04:00,HAE,neutral
595277.0,Haemonetics Corporation Appoints Ron Gelbman as Interim CEO; CEO Brian Concannon Resigns,2015-09-29 16:38:00-04:00,HAE,negative
595278.0,"Haemonetics Corp. CEO Brian Concannon Resigns, Names Ron Gelbman Interim CEO",2015-09-29 16:36:00-04:00,HAE,negative
595279.0,"Haemonetics Corp Reports Q2 Adj EPS $0.35 vs Exp $0.32,. Sales $213.4M Vs Exp $215.62M",2015-07-27 06:01:00-04:00,HAE,neutral
595280.0,"Earnings Scheduled For July 27, 2015",2015-07-27 04:57:00-04:00,HAE,neutral
595281.0,Barrington Research Downgrades Haemonetics to Market Perform,2015-04-28 11:51:00-04:00,HAE,neutral
595282.0,"Haemonetics Expects FY EPS $1.98 to $2.08, $2.10 est",2015-04-27 06:04:00-04:00,HAE,neutral
595283.0,"Haemonetics Q4 EPS $0.47 vs $0.52, Revenue $226.5M vs $239.2M est",2015-04-27 06:01:00-04:00,HAE,neutral
595284.0,"Earnings Scheduled For April 27, 2015",2015-04-27 04:05:00-04:00,HAE,neutral
595285.0,"Morgan Stanley Reiterates Equal-Weight, Raises Price Target On Haemonetics As Emerging FY16 Stability Brings Search For Upside",2015-02-23 09:56:00-05:00,HAE,neutral
595286.0,Haemontics Says Winter Storm Will Force Company To Move Announcement Of Q3 Results To Thursday Jan 29,2015-01-26 11:00:00-05:00,HAE,neutral
595287.0,UPDATE: Barrington Research Assumes Coverage On Haemonetics On Positive Revenue Outlook,2014-11-20 10:06:00-05:00,HAE,positive
595288.0,"Barrington Research Assumes Haemonetics Corporation at Outperform, Announces $46.00 PT",2014-11-20 07:38:00-05:00,HAE,neutral
595289.0,"Events for the Week of Nov. 17-21, 2014",2014-11-17 13:13:00-05:00,HAE,neutral
595290.0,"Midday Losers From November 3: RCS Capital, Haemonetics, Granite Construction And More",2014-11-03 12:39:00-05:00,HAE,negative
595291.0,Haemonetics Corporation Reports Q2 EPS of $0.47 vs $0.46 Est; Revenue of $228.0M vs $229.88M Est,2014-11-03 06:01:00-05:00,HAE,neutral
595292.0,Haemonetics Reports Q1 Adjusted EPS of $0.38 vs $0.36 Est; Revenue of $224.50M vs $215.87M Est,2014-07-30 06:03:00-04:00,HAE,neutral
595293.0,From Haemonetics Investor Day Meeting: Expecting FY15 Sales $920-939M vs $929.54M Est.,2014-05-20 11:10:00-04:00,HAE,neutral
595294.0,Morgan Stanley is Not Surprised by Weak Results/Guidance from Haemonetics,2014-04-29 09:08:00-04:00,HAE,positive
595295.0,Stocks Hitting 52-Week Lows,2014-04-28 10:38:00-04:00,HAE,negative
595296.0,US Stock Futures Gain Ahead Of Home Sales Report,2014-04-28 07:27:00-04:00,HAE,positive
595297.0,Haemonetics Corporation Reports Q4 Adjusted EPS of $0.46 vs $0.58 Est; Revenue of $241.10M vs $244.87M Est,2014-04-28 06:21:00-04:00,HAE,neutral
595298.0,Haemonetics Announces $100M Share Buyback Program ,2014-04-28 06:07:00-04:00,HAE,positive
595299.0,JMP Securities Downgrades Haemonetics Corporation to Market Perform,2014-03-24 14:08:00-04:00,HAE,positive
595300.0,Haemonetics Shares Quiet as Bloomberg Highlighting Downgrade at William Blair,2014-03-24 13:16:00-04:00,HAE,positive
595301.0,"Haemonetics Offers Update on US Whole Blood Supply Tender, Says Not Selected to Supply Red Cross with Components, Sees EPS Harmed By ~$0.15",2014-03-24 08:08:00-04:00,HAE,negative
595302.0,"Barrington Research Maintains Outperform on Haemonetics Corporation, Raises PT to $50.00",2014-01-30 07:06:00-05:00,HAE,neutral
595303.0,Monday's Premarket Earnings Reports,2014-01-27 11:44:00-05:00,HAE,neutral
595304.0,Haemonetics Reports Q3 Adjusted EPS of $0.61 vs $0.60 Est; Revenue of $242.10M vs $243.77M Est,2014-01-27 06:06:00-05:00,HAE,neutral
595305.0,"Earnings Scheduled For January 27, 2014",2014-01-27 04:47:00-05:00,HAE,neutral
595306.0,Haemonetics Signs Supply Agreement to Supply HemeXcel with Certain Whole Blood Collection Components,2014-01-12 17:15:00-05:00,HAE,positive
595307.0,"Option Alert: Haemonetics Jan $40; 1,013 Contracts Traded Friday vs 103 Open Interest",2014-01-10 12:37:00-05:00,HAE,positive
595308.0,Mid-Afternoon Market Update: Markets Look to Close in the Green for the Last Session of 2013,2013-12-31 15:16:00-05:00,HAE,neutral
595309.0,Mid-Day Market Update: Oil Futures Drop; Hertz Global Shares Jump,2013-12-31 13:04:00-05:00,HAE,neutral
595310.0,Mid-Morning Market Update: Markets Open Higher; Berkshire Hathaway To Acquire Phillips 66 Flow Business For About $1.4B,2013-12-31 10:56:00-05:00,HAE,neutral
595311.0,"Benchmark Downgrades Haemonetics Corporation to Hold, Maintains $46.00 PT",2013-12-31 10:06:00-05:00,HAE,neutral
595312.0,Benzinga's Top Downgrades ,2013-12-31 09:28:00-05:00,HAE,positive
595313.0,"US Stock Futures Flat Ahead of Consumer Confidence, House Prices Data",2013-12-31 06:57:00-05:00,HAE,positive
595314.0,"Goldman Sachs Downgrades Haemonetics Corporation to Sell, Lowers PT to $39.00",2013-12-17 07:17:00-05:00,HAE,negative
595315.0,UPDATE: Jefferies Initiates Coverage on Haemonetics as Stock is Still Dominating Blood Solutions,2013-11-26 08:53:00-05:00,HAE,negative
595316.0,Benzinga's Top Initiations,2013-11-26 07:09:00-05:00,HAE,positive
595317.0,"Jefferies Initiates Coverage on Haemonetics Corporation at Buy, Announces $48.00 PT",2013-11-26 06:30:00-05:00,HAE,neutral
595318.0,Haemonetics Corporation Reports Q2 Adjusted EPS of $0.66 vs $0.57 Est; Revenue of $235.80M vs $239.51M Est,2013-10-28 06:16:00-04:00,HAE,neutral
595319.0,CONMED Corporation Adds Two New Board Members ,2013-07-30 16:18:00-04:00,HAE,neutral
595320.0,Haemonetics Corporation Reports Q1 EPS of $0.46 vs $0.47 Est; Revenue of $219.50M vs $232.98M Est,2013-07-29 06:18:00-04:00,HAE,neutral
595321.0,UPDATE: Haemonetics Selects Sanmina for Equipment Contract Manufacturing,2013-06-19 13:56:00-04:00,HAE,neutral
595322.0,"Haemonetics to Close Operations at Italian Manufacturing Plant, Reaffirms Outlook, Says Expecting No Effect on FY14 Outlook",2013-06-19 13:55:00-04:00,HAE,negative
595323.0,"Janney Capital Initiates Coverage on Haemonetics Corporation at Buy, Announces $52.00 PT",2013-06-10 16:42:00-04:00,HAE,neutral
595324.0,Benzinga's Top Initiations,2013-06-06 08:33:00-04:00,HAE,positive
595325.0,"JMP Securities Initiates Coverage on Haemonetics Corporation at Market Outperform, Announces $52.00 PT",2013-06-06 08:23:00-04:00,HAE,positive
595326.0,William Blair Initiates Coverage on Haemonetics Corporation at Outperform,2013-06-05 07:48:00-04:00,HAE,neutral
595327.0,UPDATE: Goldman Sachs Initiates Haemonetics  at Neutral on Stable Outlook,2013-05-31 09:25:00-04:00,HAE,positive
595328.0,Benzinga's Top Initiations,2013-05-31 07:52:00-04:00,HAE,positive
595329.0,"Goldman Sachs Initiates Coverage on Haemonetics Corporation at Neutral, Announces $47.00 PT",2013-05-31 06:25:00-04:00,HAE,neutral
595330.0,From Haemonetics Presentation on Investor Day Webcast: CEO Says Expecting INcremental Enterprise Value of $1.5B Over Five Years,2013-05-16 10:22:00-04:00,HAE,positive
595331.0,"Craig-Hallum Upgrades Haemonetics Corporation to Buy, Raises PT to $47.00",2013-05-02 08:41:00-04:00,HAE,neutral
595332.0,Haemonetics Corporation Reports Q4 EPS of $0.48 vs $0.46 Est; Revenue of $249.90M vs $249.33M Est; Sees FY14 Adj. EPS $2.30-2.40 vs $2.01 Est,2013-05-01 07:44:00-04:00,HAE,neutral
595333.0,"Barrington Research Upgrades Haemonetics Corporation to Outperform, Announces $46.00 PT",2013-04-25 15:50:00-04:00,HAE,neutral
595334.0,"Mid-Afternoon Market Update: RIMM Falls Further, Endo Health Rises on Exploration of a Sale",2013-01-30 15:22:00-05:00,HAE,positive
595335.0,"Mid-Day Market Update: BlackBerry 10 Release Sends Shares Lower, Isis Pharma Boosts",2013-01-30 13:34:00-05:00,HAE,positive
595336.0,Barrington Research Downgrades Haemonetics Corporation to Market Perform,2013-01-25 15:58:00-05:00,HAE,neutral
595337.0,"Allscripts Axes CEO, Ends Plans to Sell Itself",2012-12-20 14:54:00-05:00,HAE,neutral
595338.0,Haemonetics Effects 2-for-1 Stock Split,2012-12-03 08:02:00-05:00,HAE,neutral
595339.0,From Earlier: Haemonetics Reports Q2 EPS $0.90 vs $0.77 Est; Revenues $218.2M vs $223.47M Est,2012-10-29 07:55:00-04:00,HAE,neutral
595340.0,Haemonetics Announces 2:1 Stock Split,2012-10-29 07:52:00-04:00,HAE,neutral
595341.0,UPDATE: Benchmark Initiates Haemonetics Corporation at Buy on Organic Growth  ,2012-09-13 12:02:00-04:00,HAE,positive
595342.0,Benzinga's Top Initiations,2012-09-13 07:31:00-04:00,HAE,positive
595343.0,"The Benchmark Company Initiates Coverage on Haemonetics at Buy, Announces PT of $89",2012-09-13 06:30:00-04:00,HAE,neutral
595344.0,"Barrington Research Maintains Haemonetics at Outperform, Raises PT from $73 to $79",2012-08-06 12:18:00-04:00,HAE,neutral
595345.0,Haemonetics Reports Q1 EPS $0.55 vs $0.71 Est; Revenues $176.5M vs $179.87M Est,2012-08-02 08:54:00-04:00,HAE,neutral
595346.0,Small-Cap Corner: A Forgotten Biotech ETF,2012-07-05 18:11:00-04:00,HAE,negative
595347.0,"Benzinga's Top Upgrades with Color for May 1, 2012",2012-05-01 10:15:00-04:00,HAE,positive
595348.0,UPDATE: Morgan Stanley Upgrades Haemonetics; Removes PT,2012-05-01 08:41:00-04:00,HAE,neutral
595349.0,"Morgan Stanley Upgrades Haemonetics from Underweight to Equal-weight, Removes PT of $55",2012-05-01 06:16:00-04:00,HAE,neutral
595350.0,"Morgan Stanley Upgrades Haemonetics from Underweight to Equal-weight, Removes PT of $55",2012-05-01 06:04:00-04:00,HAE,neutral
595351.0,"Pall Corporation Signs Definitive Agreement to Sell its Blood Collection, Filtration and Processing Product Lines to Haemonetics for $550M",2012-04-29 12:23:00-04:00,HAE,positive
595352.0,ViroPharma Launches Hereditary Angioedema Facebook App,2012-03-29 08:06:00-04:00,HAE,neutral
595353.0,ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze with Recombinant Human Hyaluronidase ,2012-03-06 09:45:00-05:00,HAE,positive
595354.0,"Barrington Research Reiterates Haemonetics Outperform, $73 PT",2012-01-31 17:35:00-05:00,HAE,neutral
595355.0,Morgan Stanley Reports Haemonetics Recovery On Track,2012-01-31 08:21:00-05:00,HAE,neutral
595356.0,Earnings Roundup,2012-01-30 10:35:00-05:00,HAE,neutral
595357.0,UPDATE: Haemonetics Reports Upbeat Q3 Results,2012-01-30 10:23:00-05:00,HAE,neutral
595358.0,Haemonetics Reports Q3 EPS $0.86 vs $0.80 Est; Revenues $191.20M vs $186.21M Est	 			,2012-01-30 08:02:00-05:00,HAE,neutral
595359.0,Earnings Scheduled For January 30,2012-01-30 04:13:00-05:00,HAE,neutral
595360.0,Sickle Cell Knocks Out NFL Player. Can these Companies Help?,2012-01-04 12:41:00-05:00,HAE,positive
595361.0,"Brean Murray Carret Initiates Buy, $37 PT on ViroPharma",2011-12-22 10:01:00-05:00,HAE,neutral
595362.0,Piper Jaffray Maintains Overweight Rating and $25 PT on ViroPharma ,2011-12-01 07:19:00-05:00,HAE,negative
595363.0,Barrington Research Maintains Outperform on Haemonetics Corporation; PT $73 ,2011-11-01 11:49:00-04:00,HAE,neutral
595364.0,UPDATE: Morgan Keegan Lowers PT on Haemonetics to $63,2011-11-01 09:01:00-04:00,HAE,negative
595365.0,Morgan Stanley Underweight on Haemonetics,2011-11-01 08:19:00-04:00,HAE,neutral
595366.0,Morgan Keegan Lowers PT on Haemonetics to $63,2011-11-01 07:52:00-04:00,HAE,negative
595367.0,Haemonetics Corp Reports Q2 EPS $0.72 vs $0.76 Est; Revenues $179.4M vs $173.55M Est		,2011-10-31 08:01:00-04:00,HAE,neutral
595368.0,J.P. Morgan Initiates Coverage on ViroPharma Incorporated,2011-10-04 08:02:00-04:00,HAE,neutral
595369.0,"Barrington Upgrades Haemonetics To Outperform, $70 PT",2011-08-03 09:09:00-04:00,HAE,neutral
595370.0,Morgan Stanley Takes a Look at Haemonetics,2011-08-02 09:00:00-04:00,HAE,neutral
595371.0,UPDATE: Morgan Keegan Lowers PT on Haemonetics to $65,2011-08-02 08:42:00-04:00,HAE,negative
595372.0,Morgan Keegan Lowers PT on Haemonetics To $65,2011-08-02 07:12:00-04:00,HAE,negative
595373.0,Haemonetics Reports Q1 EPS $0.65 vs $0.78 Est; Revenue $170.7M vs $170.8M Est,2011-08-01 08:06:00-04:00,HAE,neutral
595374.0,Haemonetics Reports Q1 EPS $0.65 vs $0.78 Est; Revenues $170.6M vs $170.40M Est			,2011-08-01 08:01:00-04:00,HAE,neutral
595375.0,Morgan Keegan Downgrades HAE To Market Perform,2011-07-29 07:40:00-04:00,HAE,neutral
595376.0,Benzinga's Top Downgrades,2011-07-29 07:17:00-04:00,HAE,positive
595377.0,"Morgan Keegan Downgrades HAE To Market Perform, $76 PT",2011-07-29 06:37:00-04:00,HAE,neutral
595378.0,Morgan Keegan Has Outperform On Haemonetics Corporation  ,2011-07-05 13:15:00-04:00,HAE,neutral
595379.0,Jefferies Comments On ViroPharma's Cinryze Approval In Europe,2011-06-16 08:03:00-04:00,HAE,positive
595380.0,ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema,2011-06-15 10:33:00-04:00,HAE,positive
595381.0,Richard J. Meelia Elected Chairman of Haemonetics Board of Directors    ,2011-06-06 08:10:00-04:00,HAE,neutral
595382.0,Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze,2011-05-11 07:29:00-04:00,HAE,positive
595383.0,Morgan Keegan Raises PT On HAE To $76,2011-05-03 08:02:00-04:00,HAE,neutral
595384.0,Haemonetics Guides FY 2012 EPS $3.50-$3.62 vs. $3.56 Estimate (HAE),2011-05-02 08:08:00-04:00,HAE,neutral
595385.0,Haemonetics Reports it Will Buy Back Up to $50M of Stock (HAE),2011-05-02 08:07:00-04:00,HAE,neutral
595386.0,Haemonetics Reports EPS of $0.85 vs. $0.83 Estimate; Revenues $170M vs. $180.31M Estimate  (HAE),2011-05-02 08:02:00-04:00,HAE,neutral
595387.0,UPDATE: Piper Jaffray Raising Price Target On ViroPharma  (VPHM),2011-04-19 07:38:00-04:00,HAE,neutral
595388.0,Haemonetics Hits 52-Week High (HAE),2011-04-11 10:53:00-04:00,HAE,neutral
595389.0,ViroPharma Announces Cinryzeman Data Presented at 2011 AAAAI Annual Meeting  ,2011-03-22 10:21:00-04:00,HAE,neutral
595390.0,A Peek Into The Market Before The Trading Starts,2011-03-21 07:36:00-04:00,HAE,neutral
595391.0,FDA Assigns PDUFA Date for Shire's FIRAZYR for the Treatment of Acute Attacks of Hereditary Angioedema ,2011-03-21 07:17:00-04:00,HAE,negative
595392.0,Haemonetics Beats on EPS - Analyst Blog,2011-02-01 16:01:00-05:00,HAE,neutral
595393.0,Haemonetics Beats on EPS - Analyst Blog,2011-02-01 15:45:00-05:00,HAE,neutral
595394.0,"Morgan Keegan Maintains OP Rating, $71 PT On HAE",2011-02-01 08:01:00-05:00,HAE,neutral
595395.0,Haemonetics Reports Q3 EPS of $.89 vs. $.82,2011-01-31 08:07:00-05:00,HAE,neutral
595396.0,"Benzinga's Top Downgrades (TLB, NBL, INTC, HAE)",2011-01-03 08:13:00-05:00,HAE,positive
595397.0,Morgan Stanley Downgrades HAE To Underweight,2011-01-03 06:51:00-05:00,HAE,neutral
595398.0,12-28-10 Daily Small Cap Market News and Stock Highlights from SmallCapVoice.com,2010-12-28 11:27:00-05:00,HAE,neutral
595399.0,Santarus and Pharming Announce Submission to FDA   ,2010-12-28 08:03:00-05:00,HAE,neutral
595400.0,Morgan Keegan Raises HAE Target From $65 To $70,2010-12-17 06:55:00-05:00,HAE,neutral
595401.0,Haemonetics Stays Neutral - Analyst Blog,2010-12-15 17:03:00-05:00,HAE,neutral
595402.0,Haemonetics Stays Neutral - Analyst Blog,2010-12-15 16:28:00-05:00,HAE,neutral
595403.0,Medical Devices Industry Outlook - Dec. 2010 - Zacks Analyst Interviews,2010-12-06 17:30:00-05:00,HAE,neutral
595404.0,Medical Devices Industry Outlook - Dec. 2010 - Industry Outlook,2010-12-06 17:30:00-05:00,HAE,neutral
595405.0,Medical Devices Industry Outlook – Dec. 2010 - Industry Outlook,2010-12-06 17:30:00-05:00,HAE,neutral
595406.0,Medical Devices Industry Outlook – Dec. 2010 - Industry Outlook,2010-12-06 16:57:00-05:00,HAE,neutral
595407.0,Positive Data on Shire's Firazyr - Analyst Blog,2010-12-06 14:08:00-05:00,HAE,positive
595408.0,Positive Data on Shire's Firazyr - Analyst Blog,2010-12-06 12:51:00-05:00,HAE,positive
595409.0,Medical Devices Industry Outlook - Dec. 2010 - Zacks Analyst Interviews,2010-12-06 00:00:00-05:00,HAE,neutral
595410.0,Medical Devices Industry Outlook - Dec. 2010 - Industry Outlook,2010-12-06 00:00:00-05:00,HAE,neutral
595411.0,Piper Jaffray Neutral On Santarus  (SNTS),2010-12-01 07:25:00-05:00,HAE,neutral
595412.0,"HAE Beats on EPS, Ups EPS Guidance - Analyst Blog",2010-11-02 09:35:00-04:00,HAE,neutral
595413.0,3Q Should Be Low-Point For Haemonetics,2010-11-02 07:44:00-04:00,HAE,neutral
595414.0,Haemonetics Reports Q2 Adjusted Earnings per Share of $0.80 ,2010-11-01 08:06:00-04:00,HAE,positive
595415.0,10 Health Care Stocks With Up to 30% Upside ,2010-10-26 12:53:00-04:00,HAE,positive
595416.0,Haemonetics Corp Enters Oversold Territory - Tale of the Tape,2010-10-20 18:54:00-04:00,HAE,neutral
595417.0,Medical Devices Industry Outlook - August 2010 - Industry Outlook,2010-08-24 19:15:00-04:00,HAE,neutral
595418.0,"HAE Beats, Reaffirms 2010 Guidance - Analyst Blog",2010-08-03 13:48:00-04:00,HAE,neutral
595419.0,"Improved Blood Management Improves Growth Opportunities For Haemonetics (HAE, GLOB)",2010-06-07 14:37:00-04:00,HAE,positive
595420.0,"IVIG Market Update (GIFLF.PK, BAX, HAE)",2010-06-01 16:08:00-04:00,HAE,neutral
595421.0,VPHM Initiates Mid-Stage Study - Analyst Blog,2010-04-06 14:00:00-04:00,HAE,neutral
595422.0,"Medical Devices Industry Update (BAX, BCR, COO, MASI, HAE)",2010-03-23 12:33:00-04:00,HAE,neutral
595423.0,3-2-10 Daily Small Cap Market News and Stock Highlights from SmallCapVoice.com,2010-03-02 11:20:00-05:00,HAE,neutral
595424.0,"Google's Most Popular Stock Searches Today, SNTS, MRK, ITVI, DYAX, SNDA",2009-12-02 09:24:00-05:00,HAE,positive
